Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue West

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Research in Social & Administrative Pharmacy : RSAP|September 5, 2020
Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertisingBridget J Kelly, Douglas J Rupert, Kathryn J Aikin, et al.
The Medical Journal of Australia|November 3, 2017
The kids are OK: it is discrimination not same-sex parents that harms childrenKen W Knight, Sarah Em Stephenson, Sue West, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Research in Social & Administrative Pharmacy : RSAP|September 5, 2020
Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertisingBridget J Kelly, Douglas J Rupert, Kathryn J Aikin, et al.
The Medical Journal of Australia|November 3, 2017
The kids are OK: it is discrimination not same-sex parents that harms childrenKen W Knight, Sarah Em Stephenson, Sue West, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Pageof 2